// App-Quantinova.ai

13401 : Resistance of Thrombus to Fibrinolysis in Patients With Chronic Thromboembolic Pulmonary Hypertension -Possible Involvement of Thrombin-Activated Fibrinolysis Inhibitor (TAFI)-

Researchers

Presenter

  • Yoshihiro Fukumoto

Principal Investigators

  • Takeshi Kawamura

  • Hisanori Horiuchi

  • Hiroaki Shimokawa

Medical Centers

  • Tohoku University, Miyagi, Japan

  • Nihon Pharmaceutical Univ, Saitama, Japan

  • Institute of development, Aging and Cancer, Tohoku University, Sendai, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic thromboembolic pulmonary hypertension

  • Pulmonary arterial hypertension

  • Venous thrombosis

Biomarkers

  • Thrombin-activatable fibrinolysis inhibitor

Drug/Treatment

  • Alprostadil

  • Monteplase

  • Evithrom

  • Mofezolac

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved